Immunitybio

Yahoo Finance • 28 days ago

ImmunityBio (IBRX) Climbs 7.76% on Europe Expansion

We recently published 10 Big Names Leaving Wall Street in the Dust; 4 at Fresh Highs. ImmunityBio Inc. (NASDAQ:IBRX) is one of the best performers on Friday. ImmunityBio jumped by 7.76 percent on Friday to close at $2.36 apiece after secu... Full story

Yahoo Finance • last month

ImmunityBio (IBRX) Slashes 9% on Lack of Leads

We recently published 10 Stocks Deep in the Red. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the worst performers on Tuesday. ImmunityBio dropped for a second day on Tuesday, shedding 9.13 percent to close at $2.09 apiece as investors repos... Full story

Yahoo Finance • last month

ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences

We recently published 10 Stocks Racking Up Big Gains. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the top performers of last week. ImmunityBio rallied for a second day on Friday, soaring 10.80 percent to end at $2.36 apiece, mimicking optim... Full story

Yahoo Finance • 2 months ago

Heights Capital Walks From Archer Aviation: What It Means for Investors

Key Points Sold 2,312,285 shares of Archer Aviation, a net change of approximately $25.09 million Post-trade stake: zero shares, valued at $0 The Archer Aviation position previously accounted for about 6.2% of the fund’s AUM as of the pri... Full story

Yahoo Finance • 2 months ago

Heights Capital Just Ditched Its $12.5 Million AMSC Stake. Here’s What That Might Mean.

Key Points Exited 340,102 shares in American Superconductor, reducing position value by $12.48 million Post-trade stake is zero shares, or $0 value The position was previously 3.3% of the fund's AUM as of the prior quarter These 10 stocks... Full story

Yahoo Finance • 2 months ago

ImmunityBio GAAP EPS of -$0.07 beats by $0.04, revenue of $32.06M beats by $0.18M

* ImmunityBio press release [https://seekingalpha.com/pr/20293555-driven-by-strong-demand-immunitybio-reports-467-percent-year-to-date-unit-growth-and-75] (IBRX [https://seekingalpha.com/symbol/IBRX]): Q3 GAAP EPS of -$0.07 beats by $0.0... Full story

Yahoo Finance • 3 months ago

AstraZeneca PLC (AZN): A Bull Case Theory

We came across a bullish thesis on AstraZeneca PLC on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on AZN. AstraZeneca PLC's share was trading at $85.31 as of October 3rd. AZN’s tra... Full story

Yahoo Finance • 4 months ago

H.C. Wainwright Reiterates Buy Rating on ImmunityBio, Keeps PT at $8

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 10, H.C. Wainwright reiterated the Buy rating on ImmunityBio, Inc. (NASDAQ:IBRX), keeping the price target at $8. Andr... Full story

Yahoo Finance • 4 months ago

ImmunityBio (IBRX) Reports Initial Study Data Showing 100% Disease Control in Patients With Recurrent Glioblastoma

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best long-term penny stocks to buy right now. On August 26, ImmunityBio, Inc. (NASDAQ:IBRX) announced the early findings of the first five recurrent glioblastoma patients that were treated with... Full story

Yahoo Finance • 5 months ago

CD19 CAR-NK therapy shows complete responses in late-stage lymphoma

CULVER CITY - ImmunityBio (NASDAQ:IBRX), a $2.34 billion market cap biotech company showing remarkable revenue growth of over 4,000% in the last twelve months, reported that its CD19 CAR-NK cell therapy has achieved complete responses in t... Full story

Yahoo Finance • 5 months ago

IBRX Sales Soar 2,540%

Key Points Revenue (GAAP) soared to $26.4 million in Q2 2025, beating GAAP revenue estimates by 14.0%. Net loss per share (GAAP) improved to ($0.10), ahead of expectations. ANKTIVA sales and international launches fueled top-line growth,... Full story

Yahoo Finance • 5 months ago

Immunitybio Inc earnings beat, revenue topped estimates

Investing.com - Immunitybio Inc (NASDAQ: IBRX) reported second quarter EPS of $-0.10, better than the analyst estimate of $-0.11. Revenue for the quarter came in at $26.43M versus the consensus estimate of $21.49M. Immunitybio Inc’s stock... Full story

Yahoo Finance • 5 months ago

VBK's Underlying Holdings Could Mean 12% Gain Potential

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 6 months ago

ImmunityBio secures $80M financing

* ImmunityBio (NASDAQ:IBRX [https://seekingalpha.com/symbol/IBRX]) has secured new financing to provide further working capital and support its ongoing business operations. * The company entered into a securities purchase agreement wit... Full story

Yahoo Finance • 6 months ago

ImmunityBio reports Q2 revenue above consensus

* ImmunityBio press release [https://seekingalpha.com/pr/20178028-immunitybio-reports-60-percent-increase-in-revenue-in-q2-2025-with-year-to-date-sales-of-43] (NASDAQ:IBRX [https://seekingalpha.com/symbol/IBRX]): Q2 revenue of $26.4M (+60... Full story

Yahoo Finance • 6 months ago

ImmunityBio’s (IBRX) ANKTIVA Gets Approved by UK’s Medicines and Healthcare Regulatory Agency

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the Best American Penny Stocks to Buy According to Analysts. On July 8, ImmunityBio, Inc. (NASDAQ:IBRX) announced that the UK’s Medicines and Healthcare products Regulatory Agency has approved ANKT... Full story

Yahoo Finance • 6 months ago

Los Angeles Times to go public, owner Soon-Shiong says

(Reuters) -The Los Angeles Times newspaper plans to go public within the next year, its owner Patrick Soon-Shiong said in a television interview on Monday, in an effort to give the public ownership of the 143-year-old publication. "We’re... Full story

Yahoo Finance • 6 months ago

Interesting IBRX Call Options For September 19th

Investors in ImmunityBio Inc (Symbol: IBRX) saw new options begin trading today, for the September 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IBRX options chain for the new September 19th... Full story

Yahoo Finance • 6 months ago

Exploring 3 High Growth Tech Stocks In The US Market

The U.S. market is currently experiencing a mix of volatility and optimism, with investor sentiment being influenced by renewed tariff threats and record highs in major indices like the S&P 500 and Nasdaq Composite. In this environment, id... Full story

Yahoo Finance • 6 months ago

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /CNW/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is projected to rise in th... Full story